2023-03-272024-03-312024-03-31false14761429ZOMBIE MOLECULE LTD2024-10-02iso4217:GBPxbrli:pure147614292023-03-27147614292024-03-31147614292023-03-272024-03-31147614292023-03-26147614292023-03-26147614292023-03-262023-03-2614761429bus:SmallEntities2023-03-272024-03-3114761429bus:AuditExempt-NoAccountantsReport2023-03-272024-03-3114761429bus:FullAccounts2023-03-272024-03-3114761429bus:PrivateLimitedCompanyLtd2023-03-272024-03-3114761429core:WithinOneYear2024-03-3114761429core:AfterOneYear2024-03-3114761429core:WithinOneYear2023-03-2614761429core:AfterOneYear2023-03-2614761429core:ShareCapital2024-03-3114761429core:SharePremium2024-03-3114761429core:RevaluationReserve2024-03-3114761429core:OtherReservesSubtotal2024-03-3114761429core:RetainedEarningsAccumulatedLosses2024-03-3114761429core:ShareCapital2023-03-2614761429core:SharePremium2023-03-2614761429core:RevaluationReserve2023-03-2614761429core:OtherReservesSubtotal2023-03-2614761429core:RetainedEarningsAccumulatedLosses2023-03-2614761429core:LandBuildings2024-03-3114761429core:PlantMachinery2024-03-3114761429core:Vehicles2024-03-3114761429core:FurnitureFittings2024-03-3114761429core:OfficeEquipment2024-03-3114761429core:NetGoodwill2024-03-3114761429core:IntangibleAssetsOtherThanGoodwill2024-03-3114761429core:ListedExchangeTraded2024-03-3114761429core:UnlistedNon-exchangeTraded2024-03-3114761429core:LandBuildings2023-03-2614761429core:PlantMachinery2023-03-2614761429core:Vehicles2023-03-2614761429core:FurnitureFittings2023-03-2614761429core:OfficeEquipment2023-03-2614761429core:NetGoodwill2023-03-2614761429core:IntangibleAssetsOtherThanGoodwill2023-03-2614761429core:ListedExchangeTraded2023-03-2614761429core:UnlistedNon-exchangeTraded2023-03-2614761429core:LandBuildings2023-03-272024-03-3114761429core:PlantMachinery2023-03-272024-03-3114761429core:Vehicles2023-03-272024-03-3114761429core:FurnitureFittings2023-03-272024-03-3114761429core:OfficeEquipment2023-03-272024-03-3114761429core:NetGoodwill2023-03-272024-03-3114761429core:IntangibleAssetsOtherThanGoodwill2023-03-272024-03-3114761429core:ListedExchangeTraded2023-03-272024-03-3114761429core:UnlistedNon-exchangeTraded2023-03-272024-03-3114761429core:MoreThanFiveYears2023-03-272024-03-3114761429core:Non-currentFinancialInstruments2024-03-3114761429core:Non-currentFinancialInstruments2023-03-2614761429dpl:CostSales2023-03-272024-03-3114761429dpl:DistributionCosts2023-03-272024-03-3114761429core:LandBuildings2023-03-272024-03-3114761429core:PlantMachinery2023-03-272024-03-3114761429core:Vehicles2023-03-272024-03-3114761429core:FurnitureFittings2023-03-272024-03-3114761429core:OfficeEquipment2023-03-272024-03-3114761429dpl:AdministrativeExpenses2023-03-272024-03-3114761429core:NetGoodwill2023-03-272024-03-3114761429core:IntangibleAssetsOtherThanGoodwill2023-03-272024-03-3114761429dpl:GroupUndertakings2023-03-272024-03-3114761429dpl:ParticipatingInterests2023-03-272024-03-3114761429dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-272024-03-3114761429core:ListedExchangeTraded2023-03-272024-03-3114761429dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-272024-03-3114761429core:UnlistedNon-exchangeTraded2023-03-272024-03-3114761429dpl:CostSales2023-03-262023-03-2614761429dpl:DistributionCosts2023-03-262023-03-2614761429core:LandBuildings2023-03-262023-03-2614761429core:PlantMachinery2023-03-262023-03-2614761429core:Vehicles2023-03-262023-03-2614761429core:FurnitureFittings2023-03-262023-03-2614761429core:OfficeEquipment2023-03-262023-03-2614761429dpl:AdministrativeExpenses2023-03-262023-03-2614761429core:NetGoodwill2023-03-262023-03-2614761429core:IntangibleAssetsOtherThanGoodwill2023-03-262023-03-2614761429dpl:GroupUndertakings2023-03-262023-03-2614761429dpl:ParticipatingInterests2023-03-262023-03-2614761429dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-262023-03-2614761429core:ListedExchangeTraded2023-03-262023-03-2614761429dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-262023-03-2614761429core:UnlistedNon-exchangeTraded2023-03-262023-03-2614761429core:NetGoodwill2024-03-3114761429core:IntangibleAssetsOtherThanGoodwill2024-03-3114761429core:LandBuildings2024-03-3114761429core:PlantMachinery2024-03-3114761429core:Vehicles2024-03-3114761429core:FurnitureFittings2024-03-3114761429core:OfficeEquipment2024-03-3114761429core:AfterOneYear2024-03-3114761429core:WithinOneYear2024-03-3114761429core:ListedExchangeTraded2024-03-3114761429core:UnlistedNon-exchangeTraded2024-03-3114761429core:ShareCapital2024-03-3114761429core:SharePremium2024-03-3114761429core:RevaluationReserve2024-03-3114761429core:OtherReservesSubtotal2024-03-3114761429core:RetainedEarningsAccumulatedLosses2024-03-3114761429core:NetGoodwill2023-03-2614761429core:IntangibleAssetsOtherThanGoodwill2023-03-2614761429core:LandBuildings2023-03-2614761429core:PlantMachinery2023-03-2614761429core:Vehicles2023-03-2614761429core:FurnitureFittings2023-03-2614761429core:OfficeEquipment2023-03-2614761429core:AfterOneYear2023-03-2614761429core:WithinOneYear2023-03-2614761429core:ListedExchangeTraded2023-03-2614761429core:UnlistedNon-exchangeTraded2023-03-2614761429core:ShareCapital2023-03-2614761429core:SharePremium2023-03-2614761429core:RevaluationReserve2023-03-2614761429core:OtherReservesSubtotal2023-03-2614761429core:RetainedEarningsAccumulatedLosses2023-03-2614761429core:NetGoodwill2023-03-2614761429core:IntangibleAssetsOtherThanGoodwill2023-03-2614761429core:LandBuildings2023-03-2614761429core:PlantMachinery2023-03-2614761429core:Vehicles2023-03-2614761429core:FurnitureFittings2023-03-2614761429core:OfficeEquipment2023-03-2614761429core:AfterOneYear2023-03-2614761429core:WithinOneYear2023-03-2614761429core:ListedExchangeTraded2023-03-2614761429core:UnlistedNon-exchangeTraded2023-03-2614761429core:ShareCapital2023-03-2614761429core:SharePremium2023-03-2614761429core:RevaluationReserve2023-03-2614761429core:OtherReservesSubtotal2023-03-2614761429core:RetainedEarningsAccumulatedLosses2023-03-2614761429core:AfterOneYear2023-03-272024-03-3114761429core:WithinOneYear2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:CostValuation2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-272024-03-3114761429core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3114761429core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3114761429core:Non-currentFinancialInstrumentscore:CostValuation2023-03-2614761429core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-2614761429core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-2614761429bus:Director12023-03-272024-03-31

ZOMBIE MOLECULE LTD

Registered Number
14761429
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2024

ZOMBIE MOLECULE LTD
Company Information
for the period from 27 March 2023 to 31 March 2024

Director

DAINES, Timothy Paul

Registered Address

109 Berry Lane
Langdon Hills
Basildon
SS16 6AN

Registered Number

14761429 (England and Wales)
ZOMBIE MOLECULE LTD
Balance Sheet as at
31 March 2024

Notes

2024

£

£

Fixed assets
Intangible assets36,500
Tangible assets41,720
8,220
Current assets
Debtors18,689
Cash at bank and on hand9,097
27,786
Creditors amounts falling due within one year5(8,299)
Net current assets (liabilities)19,487
Total assets less current liabilities27,707
Provisions for liabilities6(327)
Net assets27,380
Capital and reserves
Called up share capital1
Profit and loss account27,379
Shareholders' funds27,380
The financial statements were approved and authorised for issue by the Director on 2 October 2024, and are signed on its behalf by:
DAINES, Timothy Paul
Director
Registered Company No. 14761429
ZOMBIE MOLECULE LTD
Notes to the Financial Statements
for the period ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Cryptocurrency assets
Cryptocurrency assets (under IAS 38) are recorded as intangible assets and can be measured at either cost or revaluation. The company has elected to measure them at revaluation as there is now an active market across across many digital exchanges. Therefore, these are recognised at fair value. The assets are held for investment purposes and therefore cannot be recognised as stock as they are not being held for sale in the ordinary course of business.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Office Equipment25
2.Average number of employees

2024
Average number of employees during the year1
3.Intangible assets

Other

Total

££
Cost or valuation
Additions6,5006,500
At 31 March 246,5006,500
Net book value
At 31 March 246,5006,500
At 26 March 23--
4.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions1,8681,868
At 31 March 241,8681,868
Depreciation and impairment
Charge for year148148
At 31 March 24148148
Net book value
At 31 March 241,7201,720
At 26 March 23--
5.Creditors: amounts due within one year

2024

£
Taxation and social security7,325
Other creditors473
Accrued liabilities and deferred income501
Total8,299
6.Provisions for liabilities

2024

£
Net deferred tax liability (asset)327
Total327